CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 41 enrolled
Drug / intervention
ABI-007drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02103062
NCT02103062Phase 2Completed
CompareCT.gov

A SINGLE ARM PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF Nab®-PACLITAXEL, IN SUBJECTS WITH PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER

Celgene·interventional·Posted Apr 3, 2014·Updated Apr 21, 2020

In Brief

A Phase 2 clinical trial evaluating ABI-007 for Colorectal Neoplasms. Completed, enrolled 41 participants across 6 sites.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of Abraxane (nab-paclitaxel) in subjects with previously treated metastatic colorectal cancer. Subjects will be placed into two separate cohorts based on their RAS mutation status.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Neoplasms
CountriesFrance
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 3, 2014
Enrollment StartMay 5, 2014
Primary CompletionNov 10, 2014
Study CompletionJan 9, 2015
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 12.2 years ago

Interventions

ABI-007drug